Amryis wins funds for drug manufacturing

The US Department of Health and Human Services has awarded $12.3 million to the synthetic biology firm Amyris to develop domestic manufacturing for three small-molecule drugs on the Food and Drug Administration’s drug shortage list. Over the next 2 years, the firm will work with HHS to select and advance targets on the basis of Amyris’s technical capabilities. The award is part of a push from the Joe Biden Administration to deploy federal funds toward shoring up the domestic supply chain for chemicals, especially via biomanufacturing.